Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near
Altimmune Inc ALT
$2.61
▲ +0.77%
(+$0.02)
Open
$2.61
Prev Close
$2.59
Day Range
$2.58 – $2.66
52W Range
$2.56 – $7.73
Market Cap
$507.58M
Beta
0.27
EPS (TTM)
$-0.92
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2005-10-06 |
| Shares Out. | 194,470,000 |
| Website | altimmune.com/ ↗ |
| Phone | 12406541450 |
Altimmune Inc is a publicly traded company under the ticker symbol ALT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-06-01)
📰 Latest News for ALT
Altimmune, Inc. (ALT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight
ALT and the Rise of Dual Agonists Targeting Liver Disease
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial